10 results about "Proteus mirabilis" patented technology

The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.

The application discloses a cadmium-resistant proteus mirabilis and application thereof in treatment of composite pollution environment. Priestia megaterium The application provides a PBAT-degrading bacterium, i.e., a proteus mirabilis (S261-3) strain, which can grow at a temperature of 10-50 DEG C and has certain salt and cadmium resistance, and can grow normally in a high-salt or high-cadmium concentration range. Meanwhile, the S261-3 strain has a good PBAT-degrading effect, and can degrade PBAT under cadmium stress, and can be used for degrading plastic pollutants in cadmium-polluted soil. The microbial strain provided by the application has stronger adaptability to a polluted environment, meets the repair demand of a composite pollution site, can be used for comprehensive treatment of microplastic and heavy metal composite pollution, is helpful to improving soil quality and improving land utilization efficiency, and has important practical significance for soil composite pollution repair.

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

The invention belongs to the technical field of biological medicine, and discloses an auxiliary marker for diagnosing atherosclerotic plaque instability and acute coronary syndrome and application of the auxiliary marker. The auxiliary marker is selected from at least one of the following: a) proteus mirabilis; b) extracellular vesicles derived from proteus mirabilis; and c) HpmA in the extracellular vesicles. The auxiliary marker is used for preparing a product for diagnosing, screening or evaluating atherosclerotic plaque instability and / or acute coronary syndrome. It is proved that proteus mirabilis is remarkably enriched in ACS patients, and extracellular vesicles carrying HpmA penetrate through intestinal barriers and are enriched at atherosclerotic plaques. The vesicles inhibit FAK / SRC signal channels through HpmA, induce phenotypic transformation of VSMC and promote plaque instability, and an action target and a screening model are provided for drug development. Detection is carried out through non-invasive samples such as excrement or blood, and the method is easy to popularize.

This invention discloses a cholesterol-regulated bio-hybrid nanoparticle formulation, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method includes: preparing a gold nanoparticle solution; mixing the gold nanoparticle solution with a photosynthetic bacteria culture to obtain a PSB@GNP complex; mixing the PSB@GNP complex with a Proteus mirabilis culture to obtain a PM-PSB@GNP core solution; and modifying the PM-PSB@GNP core solution with a coating solution followed by spray drying to obtain the bio-hybrid nanoparticle formulation EC-PM-PSB@GNP. The preparation process of this invention is simple and controllable, requiring no complex or precise equipment. Oral administration is convenient, resulting in high patient compliance. Compared to traditional chemical drugs and injectable formulations, it significantly reduces systemic toxicity and environmental pollution risks, while also reducing treatment procedures and medication costs, achieving efficient, safe, and precise colorectal cancer treatment and meeting clinical application needs.

The invention provides clostridium butyricum pandaZhang, a microbial agent, a bacteriostatic agent and application of the clostridium butyricum pandaZhang, and belongs to the technical field of microorganisms. The preservation number of the clostridium butyricum pandaZhang is CCTCC (China Center for Type Culture Collection) NO: M 20253041. The clostridium butyricum pandaZhang is strong in antibacterial ability and wide in antibacterial spectrum, can generate antibacterial active substances such as lanheheptide through metabolism, and has a remarkable inhibition effect on various pathogenic bacteria such as escherichia coli, staphylococcus aureus, klebsiella pneumoniae, salmonella and proteus mirabilis. The strain has outstanding short-chain fatty acid production capacity, and can efficiently produce key metabolites such as propionic acid and butyric acid. When the strain is applied to breeding of weaned piglets, the growth performance of the piglets can be remarkably improved, the diarrhea rate of the weaned piglets is reduced, the intestinal health of the piglets is improved, and healthy and efficient breeding of the piglets under the antibiotic-free condition is achieved.

The invention belongs to the technical field of biology, and relates to a salmonella targeted antibacterial peptide Yisi-1 and application thereof. The amino acid sequence of the targeted antibacterial peptide Yisi-1 is alanine, isoleucine, lysine, glycine, valine, lysine, alanine, glycine, isoleucine, arginine, leucine, glycine, lysine, lysine, glycine, leucine, arginine and alanine, and the amino acid sequence of the targeted antibacterial peptide Yisi-1 is shown in the description. The molecular weight of the targeted antibacterial peptide Yisi-1 is 1836.3 Da, the isoelectric point of the targeted antibacterial peptide Yisi-1 is 12.1, and the targeted antibacterial peptide Yisi-1 has six positive charges, is high in amphipathy, has no bacteriostatic activity on staphylococcus aureus, escherichia coli, proteus mirabilis, pseudomonas aeruginosa, candida albicans and the like, only has bacteriostatic activity on salmonella, and has relatively low hemolytic activity on chicken erythrocytes. The targeted antibacterial peptide Yisi-1 disclosed by the invention is expected to become a novel antibiotic substitute and has a good application prospect in prevention, diagnosis, treatment and identification of salmonella and infection thereof.

The application provides a device for predicting the curative effect of immunotherapy for lung squamous carcinoma patients, which comprises a detection unit and a data analysis unit, wherein the detection unit extracts 9 intratumor bacterial genera as characteristic intratumor bacterial genera based on 16S rRNA sequencing data of a tumor puncture sample of a lung squamous carcinoma patient; the data analysis unit constructs a data model for predicting the curative effect of immunotherapy based on the characteristic intratumor bacterial genera and the 16S rRNA sequencing data of the tumor puncture sample of the lung squamous carcinoma patient; and the characteristic intratumor bacterial genera comprise Actinoplanes, Anaerobisporus, Cato, Fingoldia, Koch, Limnohabitans, Pararhodobacter, Achromobacter and Proteus. The prediction device can predict whether the immunotherapy for lung squamous carcinoma patients is effective, and can be used for screening and stratified management of patients before treatment, so as to guide individualized medication and improve the curative effect.

This invention discloses primers and a detection method for triple PCR detection of *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis*. The primers are Mm-F, Mm-R, ureC-F, ureC-R, trpD-F, and trpD-R, with nucleotide sequences shown in SEQ ID NO. 1–6. This invention provides a triple PCR detection method for simultaneously detecting *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis*. This method is highly specific, sensitive, rapid, and accurate, and can be used for clinical and laboratory PCR detection of *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis* in alligator gout. It has broad application potential in rapid pathogen detection and epidemiological investigation of alligator gout.